The unanimous vote by the 16 advisers recommends a formula aimed at combating the variant JN.1, which dominated infections in the United States in February, or a version of it.
In recent weeks, JN.1 has been overtaken by descendants known as KP.2 and KP.3.
is expected to formally recommend a variant target for vaccine makers for the next round of shots in the late summer or early fall.
Any decision involves some educated guesswork, given that any new vaccine formula won’t be available until months after a variant becomes dominant.
“It’s becoming clear that the ideal timing for a vaccine composition decision remains elusive,” said Jerry Weir, an official with the F.D.A.’s vaccine division.
Persons:
”, Jerry Weir
Organizations:
Food and Drug Administration
Locations:
United States